Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05127824 · ClinicalTrials.gov registry record · Phase 2
Autologous Dendritic Cell Vaccine in Kidney Cancer
A Phase 2 study of Carcinoma, Renal Cell, sponsored by Jodi Maranchie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT05127824 is a Phase 2 study of Carcinoma, Renal Cell that is actively recruiting participants, run by Jodi Maranchie. The registered enrollment target is 42 participants, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05127824, a Phase 2 study of Carcinoma, Renal Cell, is actively recruiting participants, sponsored by Jodi Maranchie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.
Conditions Studied
Interventions
- DRUG Cabozantinib
- BIOLOGICAL Autologous alpha-DC1/TBVA vaccine
Study Locations (1)
Pennsylvania
- UPMC Department of Urology - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05127824
The ClinicalTrials.gov registry entry for NCT05127824 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (85% lower). The listed sponsor is Jodi Maranchie, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 2 interventions - of which Cabozantinib is the first listed.
NCT05127824 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05127824 about?
NCT05127824 is a clinical study titled "Autologous Dendritic Cell Vaccine in Kidney Cancer". The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.
What is the current status of trial NCT05127824?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2023-07-06. Estimated completion is 2026-12.
What conditions does trial NCT05127824 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell.
What interventions are being tested in trial NCT05127824?
The interventions under investigation include: Cabozantinib (DRUG), Autologous alpha-DC1/TBVA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05127824?
This trial is sponsored by Jodi Maranchie, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05127824 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
COMPLETED · Phase 2
-
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
COMPLETED · Phase 2
-
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
COMPLETED · Phase 2
-
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
COMPLETED · Phase 2
-
Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.